Daniel Gordon Kirby - Feb 10, 2025 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Commercial Officer
Signature
/s/ Daniel Gordon Kirby
Stock symbol
IOVA
Transactions as of
Feb 10, 2025
Transactions value $
$0
Form type
4
Date filed
2/12/2025, 05:17 PM
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Stock Options (Right to Buy) Award $0 +35K $0.00 35K Feb 10, 2025 Common stock 35K $5.32 Direct F1
transaction IOVA Restricted Stock Units Award $0 +120K $0.00 120K Feb 10, 2025 Common stock 120K Direct F1, F2
transaction IOVA Performance Stock Units Award $0 +150K $0.00 150K Feb 10, 2025 Common stock 150K Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3 Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.
F4 Up to 150,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain financial milestones.
F5 Such earned PSUs shall vest on the date that the Issuer publicly announces its 2025 financial results by filing its Form 10-K with the U.S. Securities and Exchange Commission.